The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials
- PMID: 19628188
- DOI: 10.1016/j.jcin.2009.05.002
The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials
Erratum in
- JACC Cardiovasc Interv. 2009 Nov;2(11):1167
Abstract
Objectives: We sought to compare the nephrotoxicity of the iso-osmolar contrast medium, iodixanol, to low-osmolar contrast media (LOCM).
Background: Contrast-induced acute kidney injury (CI-AKI) is a common cause of in-hospital renal failure. A prior meta-analysis suggested that iodixanol (Visipaque, GE Healthcare, Princeton, New Jersey) was associated with less CI-AKI than LOCM, but this study was limited by ascertainment bias and did not include the most recent randomized controlled trials.
Methods: We searched Medline, Embase, ISI Web of Knowledge, Google Scholar, Current Contents, and International Pharmaceutical Abstracts databases, and the Cochrane Central Register of Controlled Trials from 1980 to November 30, 2008, for randomized controlled trials that compared the incidence of CI-AKI with either iodixanol or LOCM. Random-effects models were used to calculate summary risk ratios (RR) for CI-AKI, need for hemodialysis, and death.
Results: A total of 16 trials including 2,763 subjects were pooled. There was no significant difference in the incidence of CI-AKI in the iodixanol group than in the LOCM group overall (summary RR: 0.79, 95% confidence interval [CI]: 0.56 to 1.12, p = 0.19). There was no significant difference in the rates of post-procedure hemodialysis or death. There was a reduction in CI-AKI when iodixanol was compared with ioxaglate (RR: 0.58, 95% CI: 0.37 to 0.92; p = 0.022) and iohexol (RR: 0.19, 95% CI: 0.07 to 0.56; p = 0.002), but no difference when compared with iopamidol (RR: 1.20, 95% CI: 0.66 to 2.18; p = 0.55), iopromide (RR: 0.93, 95% CI: 0.47 to 1.85; p = 0.84), or ioversol (RR: 0.92, 95% CI: 0.60 to 1.39; p = 0.68).
Conclusions: This meta-analysis including 2,763 subjects suggests that iodixanol, when compared with LOCM overall, is not associated with less CI-AKI. The relative renal safety of LOCM compared with iodixanol may vary based on the specific type of LOCM.
Comment in
-
The relative renal safety of iodixanol compared with low-osmolar contrast media.JACC Cardiovasc Interv. 2009 Nov;2(11):1163-4; author reply 1164. doi: 10.1016/j.jcin.2009.08.022. JACC Cardiovasc Interv. 2009. PMID: 19926063 No abstract available.
Similar articles
-
A meta-analysis of the risk of total cardiovascular events of isosmolar iodixanol compared with low-osmolar contrast media.J Cardiol. 2014 Apr;63(4):260-8. doi: 10.1016/j.jjcc.2013.11.021. Epub 2014 Jan 4. J Cardiol. 2014. PMID: 24397991 Review.
-
Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.Radiology. 2009 Jan;250(1):68-86. doi: 10.1148/radiol.2501080833. Radiology. 2009. PMID: 19092091
-
The relative renal safety of iodixanol and low-osmolar contrast media in patients undergoing percutaneous coronary intervention. Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).J Invasive Cardiol. 2010 Oct;22(10):467-72. J Invasive Cardiol. 2010. PMID: 20944185
-
Contrast-induced nephropathy in patients with diabetes mellitus between iso- and low-osmolar contrast media: A meta-analysis of full-text prospective, randomized controlled trials.PLoS One. 2018 Mar 20;13(3):e0194330. doi: 10.1371/journal.pone.0194330. eCollection 2018. PLoS One. 2018. PMID: 29558481 Free PMC article.
-
Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials.J Nephrol. 2012 May-Jun;25(3):290-301. doi: 10.5301/jn.5000067. J Nephrol. 2012. PMID: 22252847 Review.
Cited by
-
Contrast Medium Exposure During Computed Tomography and Risk of Development of End-Stage Renal Disease in Patients With Chronic Kidney Disease: A Nationwide Population-Based, Propensity Score-Matched, Longitudinal Follow-Up Study.Medicine (Baltimore). 2016 Apr;95(16):e3388. doi: 10.1097/MD.0000000000003388. Medicine (Baltimore). 2016. PMID: 27100424 Free PMC article.
-
Low incidence of nephrotoxicity following intravenous administration of iodinated contrast media: a prospective study.Eur Radiol. 2019 Jul;29(7):3927-3934. doi: 10.1007/s00330-019-06147-2. Epub 2019 Apr 11. Eur Radiol. 2019. PMID: 30989349
-
High cell density and high-resolution 3D bioprinting for fabricating vascularized tissues.Sci Adv. 2023 Feb 22;9(8):eade7923. doi: 10.1126/sciadv.ade7923. Epub 2023 Feb 22. Sci Adv. 2023. PMID: 36812321 Free PMC article.
-
Comparative effect of iso-osmolar versus low-osmolar contrast media on the incidence of contrast-induced acute kidney injury in diabetic patients: a systematic review and meta-analysis.Cancer Imaging. 2019 Jun 18;19(1):38. doi: 10.1186/s40644-019-0224-6. Cancer Imaging. 2019. PMID: 31215488 Free PMC article.
-
Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography.World J Cardiol. 2012 May 26;4(5):157-72. doi: 10.4330/wjc.v4.i5.157. World J Cardiol. 2012. PMID: 22655164 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical